The Burrill Report (July 1, 2013): Returning to Growth (.MP3,13.92 Mb)

Worldwide prescription drug sales in dollar terms fell for the first time in 2012, a result of competition from generic drugs, price controls, and austerity measures in the Eurozone. But Evaluate Pharma sees a return to modest growth in 2013 and some encouraging signs for the outlook for the industry longer term. We spoke to Jonathan de Pass, CEO of Evaluate Group, about the company’s newly released World Preview report, the growing importance of biologics as a driver of growth for the pharmaceutical industry, and why both the quantity and quality of newly approved drugs should provide encouragement to investors.

Click here to download Evaluate Pharma's World Preview 2013, Outlook to 2018: Returning to Growth.